U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep.

Cover of Clinical Review Report: Levodopa/Carbidopa (Duodopa)

Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration [Internet].

Show details

Appendix 2Literature Search Strategy

OVERVIEW
Interface:Ovid
Databases:

Embase 1974 to present

MEDLINE Daily and MEDLINE 1946 to present

MEDLINE In-Process & Other Non-Indexed Citations

Note: Subject headings have been customized for each database. Duplicates between databases were removed in Ovid.

Date of Search:February 22, 2018
Alerts:Bi-Weekly search updates until July 12, 2018
Study Types:No search filters were applied
Limits:

No date limits; No language limits

Human filter was applied

Conference abstracts were excluded

SYNTAX GUIDE
/At the end of a phrase, searches the phrase as a subject heading
.shAt the end of a phrase, searches the phrase as a subject heading
MeSHMedical Subject Heading
fsFloating subheading
expExplode a subject heading
*Before a word, indicates that the marked subject heading is a primary topic; or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings
#Truncation symbol for one character
?Truncation symbol for one or no characters only
ADJ#Adjacency within # number of words (in any order)
.tiTitle
.abAbstract
.otOriginal title
.hwHeading Word; usually includes subject headings and controlled vocabulary
.kfAuthor keyword heading word (MEDLINE)
.kwAuthor keyword (Embase)
.ptPublication type
.poPopulation group [PsycInfo only]
.rnCAS registry number
.nmName of substance word
pmezOvid database code; MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily and Ovid MEDLINE 1946 to Present
oemezdOvid database code; Embase 1974 to present, updated daily
MULTI-DATABASE STRATEGY
#Searches
1(duodopa* or duopa* or (carbidopa* adj4 levodopa*) or (carbidopa* adj4 L-dopa*) or carbilev* or CHF 1512 or co-careldopa* or DM 1992 or dopabain* or “IPX 066” or IPX066 or isicom or rytary* or tidomed* or numient* or nacom* or “ND 0612” or ND0612 or parcopa* or sinemet*).ti,ab,ot,kf,hw,rn,nm.
2carbidopa/
3(carbidopa* or carbidopum or methyldopahydrazine* or methyldopa-hydrazine* or alpha-methyldopahydrazine* or alpha-methyl-dopa-hydrazine* or alpha-methyl-alpha-hydrazinodopa* or lodosin* or lodosyn* or carboxydopa* or hydrazinomethyldopa* or CCRIS5093 or n-aminomethyldopa or KR87B45RGH or MK-486 or MK 486 or MK486 or MK 485 or MK-485 or MK485).ti,ab,ot,kf,hw,rn,nm.
42 or 3
5levodopa/
6(levodopa* or levodopum* or L-dopa or larodopa* or levodopa* or levopa* or levopa* or dopaflex* or dopar* or bendopa* or berkdopa* or biodopa* or brocadopa* or cerepap* or cerepar* or cidandopa* or deadopa* or dopa* or dopar* or dopaflex* or dopaidan* or dopal* or dopalina* or dopasol* or dopaston* or dopastral* or doprin* or doparkine* or eldopal* or eldopar* or eldopatec* or eurodopa* or helfo dopa or helfo-dopa or helfodopa* or inbrija* or insulamina* or maipedopa* or pardopa* or prodopa* or rigakin* or rigikin* or rigitrem* or speciadopa* or sobiodopa* or syndopa* or veldopa* or CCRIS 3766 or CVT-301 or HSDB 3348 or NSC 118381 or Ro 4-6316 or 46627O600J).ti,ab,ot,kf,hw,rn,nm.
75 or 6
84 and 7
91 or 8
10gels/ or infusions, parenteral/
11(gel or gels or gelatum or jell).ti,ab,ot,kf,hw.
12(tube* or enteral or intraduodenal or infusion* or (continuous adj3 (delivery or administration or treatment)) or pump* or gastrostomy or jejunostomy or gastrojejeunostomy or duodenal or parenteral or duodenum or intubation or jejunal or ((PEG-J or PEG) adj4 tube) or (NJ adj4 tube)).ti,ab,ot,kf,hw.
1310 or 11 or 12
149 and 13
1514 use medall
16*carbidopa plus levodopa/
17(duodopa* or duopa* or (carbidopa* adj4 levodopa*) or (carbidopa* adj4 L-dopa*) or carbilev* or CHF 1512 or co-careldopa* or DM 1992 or dopabain* or “IPX 066” or IPX066 or isicom or rytary* or tidomed* or numient* or nacom* or “ND 0612” or ND0612 or parcopa* or sinemet*).ti,ab,ot,kw.
1816 or 17
19*carbidopa/
20(carbidopa* or carbidopum or methyldopahydrazine* or methyldopa-hydrazine* or alpha-methyldopahydrazine* or alpha-methyl-dopa-hydrazine* or alpha-methyl-alpha-hydrazinodopa* or lodosin* or lodosyn* or carboxydopa* or hydrazinomethyldopa* or CCRIS5093 or n-aminomethyldopa or KR87B45RGH or MK-486 or MK 486 or MK486 or MK 485 or MK-485 or MK485).ti,ab,ot,kw.
2119 or 20
22*levodopa/
23(levodopa* or levodopum* or L-dopa or larodopa* or levodopa* or levopa* or levopa* or dopaflex* or dopar* or bendopa* or berkdopa* or biodopa* or brocadopa* or cerepap* or cerepar* or cidandopa* or deadopa* or dopa* or dopar* or dopaflex* or dopaidan* or dopal* or dopalina* or dopasol* or dopaston* or dopastral* or doprin* or doparkine* or eldopal* or eldopar* or eldopatec* or eurodopa* or helfo dopa or helfo-dopa or helfodopa* or inbrija* or insulamina* or maipedopa* or pardopa* or prodopa* or rigakin* or rigikin* or rigitrem* or speciadopa* or sobiodopa* or syndopa* or veldopa* or CCRIS 3766 or CVT-301 or HSDB 3348 or NSC 118381 or Ro 4-6316 or 46627O600J).ti,ab,ot,kw.
2422 or 23
2521 and 24
2618 or 25
27exp gel/ or exp parenteral drug administration/
28(gel or gels or gelatum or jell).ti,ab,ot,kw.
29(tube* or enteral or intraduodenal or infusion* or (continuous adj3 (delivery or administration or treatment)) or pump* or gastrostomy or jejunostomy or gastrojejeunostomy or duodenal or parenteral or duodenum or intubation or jejunal or ((PEG-J or PEG) adj4 tube) or (NJ adj4 tube)).ti,ab,ot,kw.
3027 or 28 or 29
3126 and 30
3231 use oemezd
33conference abstract.pt.
3432 not 33
3515 or 34
36exp animals/
37exp animal experimentation/ or exp animal experiment/
38exp models animal/
39nonhuman/
40exp vertebrate/ or exp vertebrates/
41or/36-40
42exp humans/
43exp human experimentation/ or exp human experiment/
44or/42-43
4541 not 44
4635 not 45
47remove duplicates from 46
OTHER DATABASES
PubMedA limited PubMed search was performed to capture records not found in MEDLINE. Same MeSH, keywords, limits, and study types used as per MEDLINE search, with appropriate syntax used.
Trial registries (Clinicaltrials​.gov and others)Same keywords, limits used as per MEDLINE search.

Grey Literature

Dates for Search:February 2018
Keywords:Duodopa (carbidopa and levodopa), motor fluctuations in patients with advanced Parkinson’s disease
Limits:No date or language limits used

Relevant websites from the following sections of the CADTH grey literature checklist, Grey matters: a practical tool for evidence-based searching (http://www.cadth.ca/en/resources/finding-evidence-is/grey-matters) were searched:

  • Health Technology Assessment Agencies
  • Health Economics
  • Clinical Practice Guidelines
  • Drug and Device Regulatory Approvals
  • Advisories and Warnings
  • Drug Class Reviews
  • Databases (free)
  • Internet Search

Copyright © 2018 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK539563

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (998K)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...